Abstract：
Pulmonary arterial hypertension (PAH), one subtype of pulmonary hypertension (PH), is a life-threatening condition characterized by pulmonary arterial remodeling, elevated pulmonary vascular resistance, and blood pressure in the pulmonary arteries, leading to right heart failure and increased mortality. The disease is marked by endothelial dysfunction, vasoconstriction, and vascular remodeling. The role of Sodium-Glucose Co-Transporter-2 (SGLT2) inhibitors, a class of medications originally developed for diabetes management, is increasingly being explored in the context of cardiovascular diseases, including PAH, due to their potential to modulate these pathophysiological processes. In this review, we systematically examine the burgeoning evidence from both basic and clinical studies that describe the effects of SGLT2 inhibitors on cardiovascular health, with a special emphasis on PAH. By delving into the complex interactions between these drugs and the potential pathobiology that underpins PH, this study seeks to uncover the mechanistic underpinnings that could justify the use of SGLT2 inhibitors as a novel therapeutic approach for PAH. We collate findings that illustrate how SGLT2 inhibitors may influence the normal function of pulmonary arteries, possibly alleviating the pathological hallmarks of PAH such as inflammation, oxidative stress, aberrant cellular proliferation, and so on. Our review thereby outlines a potential paradigm shift in PAH management, suggesting that these inhibitors could play a crucial role in modulating the disease\'s progression by targeting the potential dysfunctions that drive it. This comprehensive synthesis of existing research underscores the imperative need for further clinical trials to validate the efficacy of SGLT2 inhibitors in PAH and to integrate them into the therapeutic agents used against this challenging disease.
摘要：
肺动脉高压(PAH),肺动脉高压（PH）的一种亚型，是一种以肺动脉重塑为特征的危及生命的疾病，肺血管阻力升高，肺动脉的血压，导致右心衰竭和死亡率增加。这种疾病以内皮功能障碍为特征，血管收缩,和血管重塑。钠-葡萄糖共转运蛋白-2（SGLT2）抑制剂的作用，最初为糖尿病管理开发的一类药物，越来越多地在心血管疾病的背景下进行探索，包括PAH,由于它们调节这些病理生理过程的潜力。在这次审查中,我们系统地研究了来自基础和临床研究的新兴证据，这些研究描述了SGLT2抑制剂对心血管健康的影响，特别强调PAH。通过深入研究这些药物与潜在的病理生物学之间的复杂相互作用，本研究旨在揭示可能证明SGLT2抑制剂作为PAH新型治疗方法的机制基础.我们整理了一些发现，这些发现说明了SGLT2抑制剂如何影响肺动脉的正常功能，可能减轻PAH的病理标志，如炎症，氧化应激，异常细胞增殖，等等。因此，我们的审查概述了PAH管理的潜在范式转变，这表明，这些抑制剂可以通过靶向驱动疾病的潜在功能障碍，在调节疾病进展中发挥关键作用。现有研究的综合强调了进一步临床试验的必要性，以验证SGLT2抑制剂在PAH中的功效，并将其整合到针对这种具有挑战性的疾病的治疗剂中。
